A biopharmaceutical company called ProteKt Therapeutics is currently aiming to develop a drug for treating early stages of Alzheimer’s disease based on the research of the university’s professor Kobi Rosenblum. His findings indicate that inhibiting an enzyme believed to play an important role in the development of the disease, in partnership with pharma, may give hope for a new type of treatment to be developed.

With traditional treatments not proven to be beneficial, ProteKt Therapeutics believes developing their new mechanism could have a significant effect on the the disease and hope the same treatment, when developed, could help with other neurodegenerative diseases such as ALS, Huntington and Parkinson’s.